

# Zelira Therapeutics Ltd

09:16 22 May 2018

## Zelda Therapeutics attracts experienced biopharmaceutical managing director

Zelda Therapeutics Ltd (ASX:ZLD) has appointed Dr Richard Hopkins as its managing director commencing 1 July 2018.

Hopkins is an experienced biopharmaceutical executive with over 11 years in corporate leadership roles with public biotechnology companies.

Dr Stewart Washer will step back from his executive position but positively will revert to a non-executive director and remain with the company.

## READ: Zelda Therapeutics advancing Australia-first insomnia trial

Zelda's executive chairman Harry Karelis said: "We have achieved much since our inception in 2015 and have developed deep relationships across the globe and created significant value for our shareholders.

"As the company prepares for its next phase of growth we are very pleased to have been able to attract someone of the calibre of Richard to join the team in a leadership position.

"We are in very capable hands and we will be working closely together to build on our success to date.

"Furthermore, the options incentive package recognises the importance of aligning the interests of management with those of shareholders."

During Dr Hopkins' career he has managed and overseen several strategic alliance and licensing deals with multiple global pharmaceutical partners.


He holds a PhD in molecular biology, is an author on over 25 peer-reviewed publications and is an inventor on 17 patents and patent applications.

Most recently, he was the CEO of biotech PharmAust Ltd (ASX:PAA) and he currently serves as chair of the Western Australian Ausbiotech Committee.

**Price:** 0.081

**Market Cap:** \$96.01 m

### 1 Year Share Price Graph



### Share Information

**Code:** ZLD

**Listing:** ASX

**52 week High Low**  
0.1 0.022

**Sector:** Cannabis

**Website:** [www.zeldatherapeutics.com](http://www.zeldatherapeutics.com)

### Company Synopsis:

*Zelira Therapeutics Ltd (ASX:ZLD) is a leading global therapeutic medical cannabis company with access to the world's largest and fastest growing cannabis markets.*

action@proactiveinvestors.com.au

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +61 (0)2 9280 0700 [action@proactiveinvestors.com.au](mailto:action@proactiveinvestors.com.au)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Zelira Therapeutics Ltd named herein, including the promotion by the Company of Zelira Therapeutics Ltd in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).